PDCD1 and myeloid sarcoma: A previous study of Fingolimod-treated MS patients has confirmed that the number of Tfh cells is reduced, but the proportions of PD-1+ Tfh cells and activated Tfh cells are increased in this population (Claes et al., 2014).